Patent Term Extension U.S. vs. EU SPC vs. Japan: The Complete Strategic Guide for Pharma IP Teams
Every blockbuster drug faces the same structural threat: the clock runs out on patent protection before the manufacturer has fully […]
Branded Generics vs. Commodity Generics: How Brand Trust Wins Market Share
A bottle of metformin 500 mg from Sun Pharma and a bottle of metformin 500 mg from a Tier-3 Indian
Branded Generics vs. Commodity Generics: How Brand Trust Wins Market Share Read Post »
Patent First, Launch Faster: How Pharma Companies Align IP Filing with Commercialization to Win Market Share
Every year, drug companies leave hundreds of millions of dollars on the table. Not because their molecules fail, not because
Don’t Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in M&A Due Diligence
When Pfizer paid $11.6 billion for Array BioPharma in 2019, analysts praised the deal’s logic. Two years later, generic manufacturers
Don’t Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in M&A Due Diligence Read Post »
Beyond 20 Years: What Actually Determines a Drug’s Market Exclusivity
Ask anyone in pharma how long a drug patent lasts and they’ll say 20 years. The number is technically correct
Beyond 20 Years: What Actually Determines a Drug’s Market Exclusivity Read Post »
The Four Exclusivities Behind Every Pharma Mega-Deal
When a buyer writes a $74 billion check for a drugmaker, they are not paying for the molecule. They are
The Four Exclusivities Behind Every Pharma Mega-Deal Read Post »
Post-Approval Patents: The Hidden LOE Risk Map
Most pharmaceutical IP work gets framed as a pre-approval problem. File the composition patent during discovery, secure the use claims
Post-Approval Patents: The Hidden LOE Risk Map Read Post »
Patent Cliff Forecasting: How to Predict Drug Price Erosion Before It Happens
The most expensive number in pharmaceutical finance is the one nobody on the executive team wants to commit to: how
Patent Cliff Forecasting: How to Predict Drug Price Erosion Before It Happens Read Post »
Post-Approval Patent Strategy: How to Protect Your Drug from Regulatory and IP Risk After Approval
Every time a pharmaceutical company changes something about an approved drug, it opens two doors simultaneously. The first leads to
